Literature DB >> 31622627

A literature review on Fuchs uveitis syndrome: An update.

Yang Sun1, Yinghong Ji2.   

Abstract

Fuchs uveitis syndrome is a chronic, typically unilateral, ocular condition characterized by an asymptomatic mild inflammatory syndrome that can result in cataract and secondary glaucoma. Diagnosis is largely clinical because the etiology remains obscure. Fuchs uveitis syndrome is most likely the result of different insults or pathogenic mechanisms, including infections, autoimmune diseases, hereditary and sympathetic dysfunction. According to the infectious theory, the infection of herpes simplex virus, ocular toxoplasmosis, cytomegalovirus, rubella virus, and other viruses have been implicated in the pathogenesis of the disease. There is no indication for corticosteroid therapy in Fuchs patients, and treatment should be mostly reserved to cataract and glaucoma. Phacoemulsification with intraocular lens implantation is a safe procedure with good visual outcomes in patients with Fuchs uveitis syndrome. Glaucoma is often unresponsive to treatment and should actively be monitored both preoperatively and postoperatively in these patients. We discuss the current understanding of Fuchs uveitis syndrome from its clinical presentations through recommended management and provide a comprehensive description and the updated knowledge of its pathophysiology.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fuchs' uveitis; cataract; heterochromia; pathogenesis; secondary glaucoma

Mesh:

Year:  2019        PMID: 31622627     DOI: 10.1016/j.survophthal.2019.10.003

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  8 in total

1.  Treatment of Complications Due to Fuchs Heterochromic Iridocyclitis (FHI) - a Case Report.

Authors:  Melita Adilovic; Majda Kalabic; Arnes Cabric; Darija Becirovic
Journal:  Acta Inform Med       Date:  2022-06

2.  Commentary: Clinical pearls and pitfalls in diagnosing viral anterior uveitis.

Authors:  Uday Tekchandani; Atul Arora; Simar Rajan Singh; Mohit Dogra
Journal:  Indian J Ophthalmol       Date:  2020-09       Impact factor: 1.848

3.  Knowledge about cataract and associated factors among adults in Yirgalem town, Sidama National Regional State, southern Ethiopia, 2020: a community based cross sectional study design.

Authors:  Anteneh Fikrie; Yonatan G Mariam; Elias Amaje; Henok Bekele
Journal:  BMC Ophthalmol       Date:  2021-02-10       Impact factor: 2.209

Review 4.  Asymmetric diabetic retinopathy.

Authors:  Rajvardhan Azad; Sony Sinha; Prateek Nishant
Journal:  Indian J Ophthalmol       Date:  2021-11       Impact factor: 1.848

5.  Anterior segment structures in dark iris Chinese patients with unilateral Fuchs' uveitis syndrome.

Authors:  Yajing Cai; Wenjie Wu; Yingbin Wang; Suzhen Xiao; Yue Huang
Journal:  Int Ophthalmol       Date:  2022-04-02       Impact factor: 2.029

6.  Factors associated with low prevalence of Fuchs' uveitis syndrome in Japan.

Authors:  Yu Yoneda; Yoshihiko Usui; Rie Tanaka; Keitaro Hase; Kenichi Namba; Koju Kamoi; Hiroshi Takase; Masaki Takeuchi; Wataru Matsumiya; Sentaro Kusuhara; Atsunobu Takeda; Nobuyo Yawata; Ryoji Yanai; Tomona Hiyama; Yosuke Harada; Noriyasu Hashida; Kazuichi Maruyama; Kei Nakai; Ryo Taguchi; Toshikatsu Kaburaki; Nobuhisa Mizuki; Hiroshi Goto; Yujiro Fujino; Masaru Takeuchi
Journal:  Front Med (Lausanne)       Date:  2022-09-30

7.  Detection of Fuchs' Uveitis Syndrome From Slit-Lamp Images Using Deep Convolutional Neural Networks in a Chinese Population.

Authors:  Wanyun Zhang; Zhijun Chen; Han Zhang; Guannan Su; Rui Chang; Lin Chen; Ying Zhu; Qingfeng Cao; Chunjiang Zhou; Yao Wang; Peizeng Yang
Journal:  Front Cell Dev Biol       Date:  2021-06-18

8.  Uveitis-mediated immune cell invasion through the extracellular matrix of the lens capsule.

Authors:  JodiRae DeDreu; Sonali Pal-Ghosh; Mary J Mattapallil; Rachel R Caspi; Mary Ann Stepp; A Sue Menko
Journal:  FASEB J       Date:  2022-01       Impact factor: 5.834

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.